EGFR tyrosine kinase inhibitors (TKI) Archives

Cullinan Oncology and Taiho reunite to co-develop NSCLC drug

Acquisitions, Biopharma Companies, Business, Collaborations, EGFR exon 20 insertion mutations, EGFR tyrosine kinase inhibitors (TKI), Licensing, Non-Small Cell Lung Cancer, R&D, R&D, Taiho Pharmaceutical

Cullinan Oncology and Taiho Pharmaceutical announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize a non-small cell lung cancer (NSCLC) drug.

May 12, 2022/by BioSpace

In Expected Decision, FDA Rejects Lilly’s Sintilimab in NSCLC

Alliances, Biologics License Application (BLA), Business, Checkpoint Inhibitors, Clinical Trials, Complete Response Letter, EGFR tyrosine kinase inhibitors (TKI), Eli Lilly, FDA, Hepatocellular Carcinoma, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), PD-1 Inhibitors, R&D, Therapeutics

The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.

March 24, 2022/by BioSpace

Lung Cancer Breakthroughs Touted at ESMO 2021

AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline Data

Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.

September 20, 2021/by Andrew Humphreys

Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

September 21, 2020/by Andrew Humphreys

US FDA Accepts Regulatory Submission for Tagrisso in First-Line EGFR-Mutated Non-Small Cell Lung Cancer

Breakthrough Therapy Status, Clinical Trials, CNS, EGFR tyrosine kinase inhibitors (TKI), FDA, Metastases, Mutations, New England Journal of Medicine, Non-Small Cell Lung Cancer (NSCLC), Priority Review Status, Supplemental New Drug Application (sNDA)

AstraZeneca announced that the U.S. Food and Drug Administration accepted a supplemental New Drug Application for the use of Tagrisso (osimertinib) – a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with clinical activity against central nervous system metastases – in the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR mutations.

December 18, 2017/by Business Wire